02256 ABBISKO-B
- 3.430
- -0.130-3.65%
ABBISKO-B News
Heyu-B (02256.HK): ABSK021 overseas transaction landed to focus on pipeline clinical progress
Heyu-B (02256.HK): The core pipeline is progressing frequently, and now we are focusing on the advancement of ABSK021 Phase III
Heyu-B (02256.HK): The core drug ABSK021 international multi-center clinical phase III trial has begun, and development of multiple drugs is progressing in an orderly manner
Heyo-B (02256.HK): Excellent self-developed core pipeline ABSK021 has BIC potential
Heyo-B (02256.HK): The third phase of the CSF-1R inhibitor has set sail, waiting for differentiated innovation to be implemented
Heyu-B (02256.HK): Preliminary data on ABSK021 treatment of giant cell tumors of the tendon sheath is excellent and has global competitiveness
Heyu-B (02256.HK): Preclinical projects are progressing one after another, and many key data are expected to be read during the year
First coverage by Heyu (2256.HK): Focus on small molecule tumor treatment to create differentiated products
Heyuan (2256.HK): Focus on FGFR targets and differentiated small molecule drug development in the field of tumor immunity
Heyu-B (2256.HK): Efficiently Promoting New Drug Development and Building a Differentiated Product Pipeline
Heyu-B (2256.HK) IPO Review: Clinical-stage biopharmaceutical company committed to developing innovative small molecule oncology therapies
Heyuan (2256.HK) IPO Report: Rating: 64 Rating: Neutral
IPO News: Heyu Cayman Co., Ltd. - B (2256.HK)
Analysis
Price Target
No Data
